Marc Lippman, breast cancer expert, returns to Georgetown Lombardi

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Marc Lippman, a former director of Georgetown Lombardi Comprehensive Cancer Center, is returning as a professor in the departments of oncology and medicine at Georgetown University Medical Center, beginning July 15.

From 1988 to 2001, Lippman served as director of Georgetown Lombardi. During his tenure, he also served as chair of the Department of Oncology, and professor of oncology, medicine and pharmacology at Georgetown University Medical Center. Lippman joins Georgetown Lombardi as a member of the breast cancer program. He will also establish a laboratory and see patients with breast cancer.

Most recently, Lippman served as deputy director of Sylvester Comprehensive Cancer Center at the University of Miami as well as the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Miller School of Medicine.

Lippman is known for his work in the investigation and treatment of breast cancer. Before coming to Georgetown Lombard in 1988, he led the medical breast cancer section of the medicine branch at NCI, and was senior investigator from 1974 to 1988.

Lippman has been issued multiple patents for his work, including several related to the expression of growth factor receptors in tumor cells. He has published over 400 peer-reviewed articles and is editor-in-chief of Breast Cancer Research and Treatment.

Lippman’s wife, Nanette Bishopric, is a cardiologist and a professor of medicine at the University of Miami Miller School of Medicine, focusing on epigenetic mechanisms underlying heart failure and cancer. She plans to continue working with Lippman on several cancer projects, and will continue her clinical activities at MedStar Washington Hospital Center and MedStar Georgetown University Hospital.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login